Patents Assigned to Stemnion, Inc.
-
Patent number: 9662417Abstract: The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material.Type: GrantFiled: December 16, 2015Date of Patent: May 30, 2017Assignee: STEMNION, INC.Inventors: Larry R Brown, George L Sing
-
Patent number: 9636364Abstract: The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and/or Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and/or AMP cells.Type: GrantFiled: December 1, 2014Date of Patent: May 2, 2017Assignee: STEMNION, INC.Inventors: Larry R Brown, George L Sing, Howard C Wessel
-
Patent number: 9623089Abstract: The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).Type: GrantFiled: October 28, 2014Date of Patent: April 18, 2017Assignee: STEMNION, INC.Inventors: George L Sing, David L Steed
-
Patent number: 9574177Abstract: The invention is directed to methods for reducing the number of apoptotic cell deaths in a population of cells undergoing excessive cellular apoptosis. The invention is also directed to methods for preventing apoptotic cell death in a population of cells at risk for developing excessive cellular apoptosis. In particular, the invention is directed to methods for reducing or preventing excessive cellular apoptosis comprising exposing cells exhibiting or at risk for developing excessive cellular apoptosis to a cellular factor-containing composition called Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS), which is obtained from the culturing of Amnion-derived Multipotent Progenitor (AMP) cells, or AMP cells.Type: GrantFiled: February 11, 2015Date of Patent: February 21, 2017Assignee: STEMNION, INC.Inventors: Howard C Wessel, Richard A Banas
-
Patent number: 9486485Abstract: The invention is directed to methods for treating urushiol-induced contact dermatitis. Specifically, the invention is directed to treating and reducing inflammation associated with poison ivy, poison sumac and poison oak by administering to a subject suffering from such conditions novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: GrantFiled: March 10, 2014Date of Patent: November 8, 2016Assignee: STEMNION, INC.Inventors: Larry R Brown, Linda O Palladino
-
Patent number: 9464272Abstract: The invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this composition to promote bone growth and/or regeneration and/or repair.Type: GrantFiled: December 11, 2014Date of Patent: October 11, 2016Assignee: STEMNION, INC.Inventors: Malcolm A Meyn, III, Christopher A Fried, Donna M Olejniczak, Randall G Rupp
-
Publication number: 20160175365Abstract: The invention is directed to methods for treating disorders of amino acid metabolism, in particular, phenylketonuria (PKU). Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents or treatment modalities.Type: ApplicationFiled: February 29, 2016Publication date: June 23, 2016Applicant: Stemnion, Inc.Inventor: William J. Golden
-
Publication number: 20160106887Abstract: The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material.Type: ApplicationFiled: December 16, 2015Publication date: April 21, 2016Applicant: Stemnion, Inc.Inventors: Larry R. Brown, George L. Sing
-
Patent number: 9314487Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.Type: GrantFiled: May 13, 2014Date of Patent: April 19, 2016Assignee: STEMNION, INC.Inventors: Donna M Olejniczak, David L Steed, Randall G Rupp, George L Sing
-
Publication number: 20160081329Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: December 2, 2015Publication date: March 24, 2016Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20160015785Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: September 16, 2015Publication date: January 21, 2016Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20160000874Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: September 16, 2015Publication date: January 7, 2016Applicant: STEMNION, INC.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Patent number: 9220817Abstract: The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material.Type: GrantFiled: March 11, 2014Date of Patent: December 29, 2015Assignee: STEMNION, INC.Inventors: Larry R Brown, George L Sing
-
Publication number: 20150335712Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: May 20, 2015Publication date: November 26, 2015Applicant: STEMNION, INC.Inventors: Larry R. Brown, Richard A. Banas, Howard C. Wessel, Elise M. Gill
-
Patent number: 9186379Abstract: The invention is directed to methods for preventing and/or treating necrotizing enterocolitis. The invention is further directed to reducing inflammation of the intestinal mucosa associated with necrotizing enterocolitis. The invention is further directed to methods for preventing and/or treating necrotizing enterocolitis and/or inflammation of the intestinal mucosa associated with necrotizing enterocolitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: GrantFiled: February 19, 2014Date of Patent: November 17, 2015Assignee: STEMNION, INC.Inventor: David L Steed
-
Patent number: 9173908Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: February 5, 2015Date of Patent: November 3, 2015Assignee: STEMNION, INC.Inventors: Richard A. Banas, Catherine J. Trumpower, Vivienne S. Marshall
-
Patent number: 9173927Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: August 1, 2014Date of Patent: November 3, 2015Assignee: STEMNION, INC.Inventors: Charlotte A Emig, Catherine J Trumpower, George L Sing
-
Publication number: 20150306149Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: July 1, 2015Publication date: October 29, 2015Applicant: STEMNION, INC.Inventors: Richard A. Banas, Catherine J. Trumpower
-
Patent number: 9138443Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: July 16, 2013Date of Patent: September 22, 2015Assignee: STEMNION, INC.Inventors: Richard A Banas, Vivienne S Marshall, Catherine J Trumpower
-
Publication number: 20150202235Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: ApplicationFiled: November 20, 2014Publication date: July 23, 2015Applicant: Stemnion, Inc.Inventors: Charlotte A. Emig, Vivienne S. Marshall